Good Morning All. Excellent post Ulf53 on the tar
Post# of 721
(Total Views: 191)
Posted On: 09/25/2020 10:07:58 AM
Good Morning All. Excellent post Ulf53 on the target price of $1.20 per share estimated by MarketWatch.
I checked message boards on several other forums yesterday, and found that some are talking about a possible reverse split as a vehicle to a higher exchange. Remember, Lexaria said they have applied to a major exchange in the U.S.
So, let me address this issue. According to TDAmeritrade, Lexaria only has less then 90 million shares outstanding. If we assume the major American exchange is the NASDAQ, they look for liquidity as one of their criteria. So I suggest 90 million shares outstanding is barely liquid at all, and a reverse split would reduce that number dramatically. Therefore, I think we can safely discard that idea, and maybe even consider a forward split to help the liquidity issue.
So how do we meet the $4.00 dollar minimum for NASDAQ? I suggest the large orders Lexaria is likely to get from big tobacco (Altria license renewal is due on October 9th). I further suggest these large companies will actually pay for any future clinical trials because they will want to market their products as soon as possible.
All in my opinion, but some serious food for thought.
Kgem
I checked message boards on several other forums yesterday, and found that some are talking about a possible reverse split as a vehicle to a higher exchange. Remember, Lexaria said they have applied to a major exchange in the U.S.
So, let me address this issue. According to TDAmeritrade, Lexaria only has less then 90 million shares outstanding. If we assume the major American exchange is the NASDAQ, they look for liquidity as one of their criteria. So I suggest 90 million shares outstanding is barely liquid at all, and a reverse split would reduce that number dramatically. Therefore, I think we can safely discard that idea, and maybe even consider a forward split to help the liquidity issue.
So how do we meet the $4.00 dollar minimum for NASDAQ? I suggest the large orders Lexaria is likely to get from big tobacco (Altria license renewal is due on October 9th). I further suggest these large companies will actually pay for any future clinical trials because they will want to market their products as soon as possible.
All in my opinion, but some serious food for thought.
Kgem
(1)
(0)